文献速递血栓与止血

孤立性浅静脉血栓形成后静脉血栓栓塞症、复发及出血的发生率:来自Østfold医院静脉血栓登记研究的结果

Incidence of venous thromboembolism, recurrence, and bleeding after isolated superficial vein thrombosis: findings from the Venous Thrombosis Registry in Østfold Hospital.
PubMed 文献 · J Thromb Haemost · 2023-10-31

挪威Østfold医院静脉血栓登记研究纳入2014年1月至2021年12月229例高危孤立性浅静脉血栓形成(血栓长度≥5cm)且接受抗凝治疗的患者。1年和5年静脉血栓栓塞症累积发生率分别为4.6%和15.9%,孤立性浅静脉血栓复发累积发生率分别为6.5%和15.9%,45天重大出血和临床相关非重大出血累积发生率分别为0.4%和1.8%。结论认为尽管接受抗凝治疗,高危孤立性浅静脉血栓形成后静脉血栓栓塞症风险仍较高,而出血并发症较低。

要点

  • 高危孤立性浅静脉血栓形成(血栓长度≥5cm)抗凝治疗后5年静脉血栓栓塞症累积发生率为15.9%。
  • 1年和5年孤立性浅静脉血栓复发累积发生率分别为6.5%和15.9%。
  • 45天重大出血和临床相关非重大出血累积发生率分别为0.4%和1.8%。

核心结论

  • 尽管接受抗凝治疗,高危孤立性浅静脉血栓形成后静脉血栓栓塞症风险仍较高,而出血并发症较低。

研究设计与样本

  • 研究通过挪威Østfold医院静脉血栓登记(TROLL登记)识别2014年1月至2021年12月期间229例高危孤立性浅静脉血栓形成(血栓长度≥5cm)、无活动性癌症、无静脉血栓栓塞症或孤立性浅静脉血栓形成病史且接受抗凝治疗的患者。
  • 评估静脉血栓栓塞症和孤立性浅静脉血栓复发的累积发生率,以及重大出血和临床相关非重大出血事件的累积发生率。

主要发现

  • 中位年龄60岁(IQR,48-71),女性125例(55%)。
  • 大多数患者接受直接口服抗凝药治疗(74%),其中79%接受利伐沙班10mg每日一次剂量;26%的患者接受低分子量肝素治疗。
  • 孤立性浅静脉血栓形成后1年和5年静脉血栓栓塞症累积发生率分别为4.6%(95%CI,2.5-8.3)和15.9%(95%CI,10.8-22.9)。
  • 1年和5年孤立性浅静脉血栓复发累积发生率分别为6.5%(95%CI,3.9-10.7)和15.9%(95%CI,10.8-23.1)。
  • 45天重大出血和临床相关非重大出血事件总体累积发生率分别为0.4%(95%CI,0.06-3.06)和1.8%(95%CI,0.7-4.6);接受直接口服抗凝药治疗的患者中未观察到重大出血事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are limited data on the long-term risk of venous thromboembolism (VTE) after high-risk isolated superficial vein thrombosis (iSVT) treated with anticoagulants. OBJECTIVES: To determine the short- and long-term risk of VTE and iSVT recurrence after cessation of anticoagulant treatment and to calculate 45-day cumulative bleeding incidence in patients with iSVT. METHODS: Between January 2014 and December 2021, 229 patients with high-risk iSVT (ie, thrombus length ≥5cm), without active cancer, with no history of VTE or iSVT, and who had received anticoagulant treatment for the iSVT were identified through the Venous Thrombosis Registry in Østfold Hospital (TROLL registry), Norway. Cumulative incidences of VTE and iSVT recurrence, as well as cumulative incidences of major and clinically relevant nonmajor bleeding events, were assessed. RESULTS: Median age was 60 years (IQR, 48-71), and 125 (55%) were women. Most patients were treated with direct oral anticoagulants (74%), and of these, 79% received a dose of rivaroxaban 10 mg daily. Low-molecular-weight heparin was given to 26% of the patients. The 1- and 5-year cumulative incidences of VTE after iSVT were 4.6% (95% CI, 2.5-8.3) and 15.9% (95% CI, 10.8-22.9), respectively. Further, the 1- and 5-year cumulative incidences of iSVT recurrence were 6.5% (95% CI, 3.9-10.7) and 15.9% (95% CI, 10.8-23.1), respectively. The overall 45-day cumulative incidence of major and clinically relevant nonmajor bleeding events was 0.4% (95% CI, 0.06-3.06) and 1.8% (95% CI, 0.7-4.6), respectively. No major bleeding events were observed in patients treated with direct oral anticoagulants. CONCLUSION: Despite anticoagulant treatment, the risk of VTE after high-risk iSVT was substantial, while bleeding complications were low.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Jørgensen CT, Brækkan SK, Førsund E, et al. Incidence of venous thromboembolism, recurrence, and bleeding after isolated superficial vein thrombosis: findings from the Venous Thrombosis Registry in Østfold Hospital. J Thromb Haemost. 2023. PMID: 37913911. doi:10.1016/j.jtha.2023.10.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。